Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Single shot of Covid jab effective at preventing hospital admission

Mon, 01st Mar 2021 19:01

(Alliance News) - A single shot of the Pfizer Inc or Oxford-AstraZeneca PLC vaccine offers dramatic protection against hospital admission and severe disease in older people, according to a new study from Public Health England.

Health Secretary Matt Hancock hailed the "exciting" real-world data which found either vaccine is more than 80% effective at preventing hospital admission around three to four weeks after the first dose.

England's deputy chief medical officer Jonathan Van-Tam said the data offered a glimpse of how the vaccine programme "is going to hopefully take us into a very different world in the next few months".

The study, which has yet to be peer-reviewed, included more than 7.5 million people aged 70 and over in England.

The data also shows that infections, where people display symptoms, in the over-70s fall from around three weeks after one dose of both vaccines.

Protection against even developing symptomatic Covid-19 in the first place ranged between 57 and 61% for one dose of Pfizer and between 60% and 73% for the Oxford-AstraZeneca vaccine, the study found.

On top of the protection against symptomatic disease, people who had been vaccinated with one dose of Pfizer had an additional 43% lower risk of emergency hospital admission and an additional 51% lower risk of death, according to the study.

Meanwhile, people who had been vaccinated with one dose of the Oxford vaccine had an additional 37% lower risk of emergency hospital admission, while there is currently insufficient follow-up data to assess the impact on death.

The authors said that "both vaccines show similar effects", adding: "Combined with the effect against symptomatic disease, this indicates that a single dose of either vaccine is approximately 80% effective at preventing hospitalisation and a single dose of (Pfizer) is 85% effective at preventing death with Covid-19."

Hancock told a Downing Street press conference the study was "extremely good news".

He added: "In fact, the detailed data show that the protection that you get from catching Covid 35 days after a first jab is even slightly better for the Oxford jab than for Pfizer, albeit both results are clearly very strong."

The results "may also help to explain why the number of Covid admissions to intensive care units among people over 80 in the UK have dropped to single figures in the last couple of weeks".

Van-Tam told the briefing the data "gives us those first glimpses of how, if we are patient, and we give this vaccine programme time to have its full effect, it is going to hopefully take us into a very different world in the next few months".

Urging people to have their second doses, he added: "I think there's quite a significant likelihood that a second dose of vaccine is going to mature your immune response, possibly make it broader and almost certainly make it longer than it would otherwise be in relation to a first dose only."

That meant it was "absolutely critical" that second doses "are still part of the course of immunisation against Covid-19 and no less important for that reason".

Van-Tam said the latest scientific data had "vindicated" the UK's decision to give the AstraZeneca vaccine to older people.

Some countries have refused to administer the vaccine to the over-65s because of a lack of clinical trial data on older age groups.

However, Van-Tam said the Joint Committee on Vaccination & Immunisation had taken the view that it was "not immunologically plausible" the vaccine would work in younger age groups but not older ones.

He added: "We took a view that it almost certainly would work. The PHE data have clearly vindicated that approach today.

"I am not here to criticise other countries but to say that I think in time the data emerging from our programme will speak for itself and other countries will doubtless be very interested in it."

Mary Ramsay, PHE head of immunisation, said of the study: "This adds to growing evidence showing that the vaccines are working to reduce infections and save lives.

"While there remains much more data to follow, this is encouraging and we are increasingly confident that vaccines are making a real difference.

"It is important to remember that protection is not complete and we don't yet know how much these vaccines will reduce the risk of you passing Covid-19 on to others.

"Even if you have been vaccinated, it is really important that you continue to act like you have the virus, practise good hand hygiene and stay at home."

By Jane Kirby, PA Health Editor

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more
19 Feb 2024 08:36

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

(Alliance News) - AstraZeneca PLC on Monday announced new study data and a new approval for its cancer medication Tagrisso.

Read more
19 Feb 2024 08:03

AstraZeneca's Tagrisso gains FDA approval

(Sharecast News) - Drugmaker AstraZeneca traded higher early on Monday after revealing that a combination of its cancer drug Tagrisso with chemotherapy had gained US approval to treat a particular type of lung cancer.

Read more
19 Feb 2024 07:49

LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023

(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.